Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation. An Open Trial With Risperidone.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Severe Mood Dysregulation
- Sponsor
- Federal University of Rio Grande do Sul
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- We use as the primary outcome the subscale of irritability of the Aberrant Checklist Behavior which measures the intensity of irritability, temper tantruns and hyperarousal symptoms
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to investigate whether Risperidone is effective in children and adolescents with severe mood dysregulation.
Detailed Description
Severe Mood Dysregulation(SMD) is a new construct in children and adolescents characterized by persistent and non episodic irritability, hyperarousal and emotional reactivity. This is an open label trial using Risperidone in children and adolescents( 7-17 years old) diagnosed with SMD. We hypothesized that Risperidone would improve externalizing symptoms as well as depressive and/or maniac symptomatology. We also consider the effect of the pharmacological intervention in the co-morbid disorders especially ADHD.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnose of Severe Mood Dysregulation
- •7-17 years
Exclusion Criteria
- •Bipolar disorder
- •Psychosis
Outcomes
Primary Outcomes
We use as the primary outcome the subscale of irritability of the Aberrant Checklist Behavior which measures the intensity of irritability, temper tantruns and hyperarousal symptoms
Time Frame: 11/2010